A Phase 1 interventional study of axitinib and capecitabine in Stomach Neoplasms and Advanced Gastric Cancer, sponsored by Pfizer. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-27.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Stomach Neoplasms by Pfizer — 5 open to participants now, 7 under way, 1 of them phase 3. Stomach Neoplasms · Pfizer.
Among the 27 studies in Stomach Neoplasms by Pfizer, this one is the 23rd largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2009, is one of 18 in phase 1, and was the 7th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.
Browse Stomach Neoplasms studies →5 of the 27 studies in Stomach Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada, China and 7 more countries
Ages 18+
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, Canada, China and 7 more countries
Ages 18+
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, Belgium, Canada and 8 more countries
Ages 18+
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, France, Korea, Republic of and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 6 · Phase 3 2
First in 2002; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 66 across 2,500 interventional studies indexed under Stomach Neoplasms.
Median enrollment 79 across the 25 interventional studies, 30,936 across the 2 observational. Of the 20 that completed or were terminated, 10 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Stomach Neoplasms by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Stomach Neoplasms by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safe and tolerable dose of axitinib given together with cisplatin and capecitabine in patients with advanced gastric cancer who have not received prior chemotherapy for their advanced cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: axitinib · Drug: capecitabine · Drug: cisplatin
Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m\^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m\^2 on day 1.
Number of Participants With Cycle 1 Dose-limiting Toxicities (DLTs)
DLT = Grade (GR) 2 proteinuria; GR3 nonhematological toxicity (NHT) (excluding alopecia and those that can be controlled with appropriate treatment) for greater than or equal to (\>=)7 days, GR3 thrombocytopenia with active bleeding; GR \>=3 febrile neutropenia (NP) or NP infection; GR 3 or 4 nausea, vomiting or diarrhea despite anti-emetics, anti-diarrheals; GR4 NHT, thrombocytopenia, NP for \>=7 days; \>= 1/2 teaspoon per day hemoptysis; any treatment related toxicity with \>3 consecutive days of capecitabine or 5 consecutive days of axitinib missed doses per cycle; delayed toxicity recovery \>14 days.
Time frame: Baseline up to Day 21 of Cycle 1
Maximum Observed Plasma Concentration (Cmax) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin
Cmax for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Cmax for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-fluorouracil \[5-FU\], 5-deoxy-5-fluorouridine \[5-DFUR\] and 5-deoxy-5-fluorocytidine \[5-DFC\]) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1. Results for axitinib were normalized to axitinib 5 mg dose, results for capecitabine and its metabolites (5-FU, 5-DFUR and 5-DFC) were normalized to Cycle 1 Day 1 capecitabine dose and results for cisplatin were normalized to Cycle 1 Day 1 cisplatin dose.
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on Cycle 1 (C1) Day -1 (D-1), C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin
Tmax for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Tmax for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR and 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1.
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Capecitabine, Capecitabine's Metabolites and Cisplatin
Area under the plasma concentration time-curve from zero to the last measurable concentration (AUClast). AUClast for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR, 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1. Results for capecitabine and its metabolites (5-FU, 5-DFUR and 5-DFC) were normalized to Cycle 1 Day 1 capecitabine dose and results for cisplatin were normalized to Cycle 1 Day 1 cisplatin dose.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1
Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] for Axitinib
AUC (0-24) = Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours. AUC (0-24) for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Results for axitinib were normalized to axitinib 5 mg dose.
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1
Area Under the Curve From Time Zero Extrapolated to Infinite Time [AUC (0 - ∞)] for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) extrapolated to infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. AUC (0 - ∞) for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR and 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1. Results for axitinib were normalized to axitinib 5 mg dose, results for capecitabine and its metabolites (5-FU, 5-DFUR and 5-DFC) were normalized to Cycle 1 Day 1 capecitabine dose and results for cisplatin were normalized to Cycle 1 Day 1 cisplatin dose.
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1
Plasma Decay Half-Life (t1/2) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Plasma decay half life for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Plasma decay half life for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR and 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1.
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1
Apparent Oral Clearance (CL/F) for Axitinib, Capecitabine and Capecitabine's Metabolites
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Clearance is defined as the volume of blood from which drug can be completely removed per unit of time. CL/F for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. CL/F for capecitabine in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (capecitabine alone) on Cycle 2 Day 1.
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose on C1D1, C2D1
Clearance (CL) for Cisplatin
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It is defined as the volume of blood from which drug can be completely removed per unit of time. Clearance for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate) in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin alone) on Cycle 2 Day 1.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start on C1D1, C2D1
Apparent Volume of Distribution (Vz/F) for Axitinib, Capecitabine and Capecitabine's Metabolites
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz/F is influenced by the fraction absorbed. Vz/F for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Vz/F for capecitabine in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (capecitabine alone) on Cycle 2 Day 1.
Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose on C1D1, C2D1
Volume of Distribution (Vz) for Cisplatin
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Clearance for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate) in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin alone) on Cycle 2 Day 1.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start on C1D1, C2D1
Drug Metabolizing Enzyme Genotyping
Genetic variants of uridine diphosphate (UDP)- glucuronosyl transferase 1A1 (UGT1A1) gene which were assessed for genotyping included UGT1A1\*60, UGT1A1-3156, UGT1A1 Promoter thymine adenine (TA) repeat (UGT1A1\*28, UGT1A1\*36, UGT1A1\*37), UGT1A1\*6 and UGT1A1\*27.
Time frame: Day 1 of Cycle 1
Percentage of Participants With Objective Response (OR)
Number of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are those with disappearance of all target lesions. PR are those with at least 30 percent (%) decrease in sum of the longest dimensions of target lesions taking the baseline sum of the longest dimensions as a reference.
Time frame: Baseline up to disease progression or withdrawal, assessed on Day 21 of every other cycle starting from Cycle 2 up to Day 784
Duration of Response (DR)
Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response. CR = disappearance of all target lesions. PR = at least 30% decrease in sum of the longest dimensions of target lesions taking the baseline sum of the longest dimensions as a reference.
Time frame: Baseline up to disease progression or withdrawal, assessed on Day 21 of every other cycle starting from Cycle 2 up to Day 784
Progression-Free Survival (PFS)
Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death"). PD was a\>=20% increase in sum of the longest dimensions of target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.
Time frame: Baseline up to disease progression or withdrawal, assessed on Day 21 of every other cycle starting from Cycle 2 up to Day 784
Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Cisplatin and Capecitabine
MTD = highest dose at which no more than 30 percent (%) of 12 participants experience DLT during Cycle 1. DLT = GR2 proteinuria; GR3 NHT (excluding alopecia and those that can be controlled with appropriate treatment)for \>=7 days, GR3 thrombocytopenia with active bleeding; GR \>=3 febrile NP/NP infection; GR 3 or 4 nausea, vomiting or diarrhea despite anti-emetics, anti-diarrheals; GR4 NHT, thrombocytopenia, NP for \>=7 days; \>= 1/2 teaspoon per day hemoptysis; any treatment-related toxicity with \>3 consecutive days of capecitabine or 5 consecutive days of axitinib missed doses per cycle; delayed toxicity recovery \>14 days.
Time frame: Baseline up to Day 21 of Cycle 1
| Milestone | Axitinib + Capecitabine + Cisplatin |
|---|---|
| Started | 22 |
| Completed | 1 |
| Not completed | 21 |
| Withdrew: Death | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Other | 17 |
DLT = Grade (GR) 2 proteinuria; GR3 nonhematological toxicity (NHT) (excluding alopecia and those that can be controlled with appropriate treatment) for greater than or equal to (\>=)7 days, GR3 thrombocytopenia with active bleeding; GR \>=3 febrile neutropenia (NP) or NP infection; GR 3 or 4 nausea, vomiting or diarrhea despite anti-emetics, anti-diarrheals; GR4 NHT, thrombocytopenia, NP for \>=7 days; \>= 1/2 teaspoon per day hemoptysis; any treatment related toxicity with \>3 consecutive days of capecitabine or 5 consecutive days of axitinib missed doses per cycle; delayed toxicity recovery \>14 days.
| participants | Axitinib + Capecitabine + Cisplatin (MTD Determination) |
|---|---|
| Number of Participants With Cycle 1 Dose-limiting Toxicities (DLTs) | 3 |
MTD = highest dose at which no more than 30 percent (%) of 12 participants experience DLT during Cycle 1. DLT = GR2 proteinuria; GR3 NHT (excluding alopecia and those that can be controlled with appropriate treatment)for \>=7 days, GR3 thrombocytopenia with active bleeding; GR \>=3 febrile NP/NP infection; GR 3 or 4 nausea, vomiting or diarrhea despite anti-emetics, anti-diarrheals; GR4 NHT, thrombocytopenia, NP for \>=7 days; \>= 1/2 teaspoon per day hemoptysis; any treatment-related toxicity with \>3 consecutive days of capecitabine or 5 consecutive days of axitinib missed doses per cycle; delayed toxicity recovery \>14 days.
| mg | Axitinib + Capecitabine + Cisplatin (MTD Determination) |
|---|---|
| Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Cisplatin and Capecitabine | 5 |
Cmax for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Cmax for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-fluorouracil \[5-FU\], 5-deoxy-5-fluorouridine \[5-DFUR\] and 5-deoxy-5-fluorocytidine \[5-DFC\]) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1. Results for axitinib were normalized to axitinib 5 mg dose, results for capecitabine and its metabolites (5-FU, 5-DFUR and 5-DFC) were normalized to Cycle 1 Day 1 capecitabine dose and results for cisplatin were normalized to Cycle 1 Day 1 cisplatin dose.
| nanogram/milliliter (ng/mL) | Axitinib + Capecitabine + Cisplatin (PK Expansion Cohort) |
|---|---|
| Axitinib alone (n = 10) | 16.11 (9.94 to 26.10) |
| Axitinib in combination with chemotherapy (n = 10) | 24.33 (15.01 to 39.43) |
| Capecitabine alone (n = 8) | 5255.62 (3155.36 to 8753.85) |
| Capecitabine in presence of axitinib (n = 8) | 2274.80 (1365.74 to 3788.95) |
| 5-FU alone (n = 8) | 220.49 (132.31 to 367.44) |
| 5-FU in presence of axitinib (n = 8) | 90.97 (54.59 to 151.59) |
| 5-DFUR alone (n = 8) | 5791.81 (3871.80 to 8663.95) |
| 5-DFUR in presence of axitinib (n = 8) | 3017.27 (2017.03 to 4513.52) |
| 5-DFC alone (n = 8) | 5891.29 (4416.64 to 7858.31) |
| 5-DFC in presence of axitinib (n = 8) | 3227.57 (2419.68 to 4305.21) |
| Cisplatin alone (n = 8) | 1665.27 (1407.48 to 1970.26) |
| Cisplatin in presence of axitinib (n = 8) | 1865.07 (1576.36 to 2206.66) |
Tmax for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Tmax for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR and 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1.
| hrs | Axitinib + Capecitabine + Cisplatin (PK Expansion Cohort) |
|---|---|
| Axitinib alone (n = 10) | 3.98 (0.00 to 7.97) |
| Axitinib in combination with chemotherapy (n = 10) | 4.00 (1.00 to 6.00) |
| Capecitabine alone (n = 8) | 2.45 (0.50 to 4.00) |
| Capecitabine in presence of axitinib (n = 8) | 3.12 (0.50 to 4.02) |
| 5-FU alone (n = 8) | 2.50 (0.50 to 4.07) |
| 5-FU in presence of axitinib (n = 8) | 2.62 (0.50 to 4.02) |
| 5-DFUR alone (n = 8) | 2.50 (0.50 to 4.07) |
| 5-DFUR in presence of axitinib (n = 8) | 2.62 (0.97 to 4.02) |
| 5-DFC alone (n = 8) | 2.50 (0.50 to 4.07) |
| 5-DFC in presence of axitinib (n = 8) | 3.09 (0.50 to 4.02) |
| Cisplatin alone (n = 8) | 2.00 (1.00 to 2.20) |
| Cisplatin in presence of axitinib (n = 8) | 1.02 (0.97 to 2.33) |
Area under the plasma concentration time-curve from zero to the last measurable concentration (AUClast). AUClast for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR, 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1. Results for capecitabine and its metabolites (5-FU, 5-DFUR and 5-DFC) were normalized to Cycle 1 Day 1 capecitabine dose and results for cisplatin were normalized to Cycle 1 Day 1 cisplatin dose.
| nanogram*hour/milliliter (ng*hr/mL) | Axitinib + Capecitabine + Cisplatin (PK Expansion Cohort) |
|---|---|
| Capecitabine alone | 7109.59 (4525.07 to 11170.27) |
| Capecitabine in presence of axitinib | 4194.97 (2669.99 to 6590.95) |
| 5-FU alone | 332.37 (238.03 to 464.12) |
| 5-FU in presence of axitinib | 176.81 (126.62 to 246.89) |
| 5-DFUR alone | 9996.55 (8183.62 to 12211.10) |
| 5-DFUR in presence of axitinib | 6683.33 (5471.27 to 8163.90) |
| 5-DFC alone | 10820.14 (8838.29 to 13246.37) |
| 5-DFC in presence of axitinib | 7983.14 (6520.93 to 9773.23) |
| Cisplatin alone | 3814.93 (3463.52 to 4202.00) |
| Cisplatin in presence of axitinib | 3951.57 (3587.57 to 4352.50) |
AUC (0-24) = Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours. AUC (0-24) for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Results for axitinib were normalized to axitinib 5 mg dose.
| ng*hr/mL | Axitinib + Capecitabine + Cisplatin (PK Expansion Cohort) |
|---|---|
| Axitinib alone | 206.20 (109.20 to 389.36) |
| Axitinib in combination with chemotherapy | 265.89 (140.81 to 502.08) |
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) extrapolated to infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. AUC (0 - ∞) for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR and 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1. Results for axitinib were normalized to axitinib 5 mg dose, results for capecitabine and its metabolites (5-FU, 5-DFUR and 5-DFC) were normalized to Cycle 1 Day 1 capecitabine dose and results for cisplatin were normalized to Cycle 1 Day 1 cisplatin dose.
| ng*hr/mL | Axitinib + Capecitabine + Cisplatin (PK Expansion Cohort) |
|---|---|
| Axitinib alone (n = 9) | 147.04 (70.79 to 305.42) |
| Axitinib in combination with chemotherapy (n = 9) | 156.00 (75.10 to 324.02) |
| Capecitabine alone (n = 6) | 7140.62 (4197.86 to 12146.29) |
| Capecitabine in presence of axitinib (n = 6) | 4213.72 (2477.18 to 7167.60) |
| 5-FU alone (n = 3) | 337.85 (198.44 to 575.20) |
| 5-FU in presence of axitinib (n = 3) | 261.95 (153.86 to 445.98) |
| 5-DFUR alone (n = 4) | 9568.70 (6772.04 to 13520.28) |
| 5-DFUR in presence of axitinib (n = 4) | 6966.07 (4930.09 to 9842.84) |
| 5-DFC alone (n = 5) | 11587.97 (7974.00 to 16839.87) |
| 5-DFC in presence of axitinib (n = 5) | 7787.39 (5358.71 to 11316.78) |
| Cisplatin alone (n = 7) | 3979.07 (3577.60 to 4425.59) |
| Cisplatin in presence of axitinib (n = 7) | 3990.34 (3587.74 to 4438.12) |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Plasma decay half life for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Plasma decay half life for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR and 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1.
| hrs | Axitinib + Capecitabine + Cisplatin (PK Expansion Cohort) |
|---|---|
| Axitinib alone (n = 9) | 5.76 ± 3.665 |
| Axitinib in combination with chemotherapy (n = 9) | 3.50 ± 1.869 |
| Capecitabine alone (n = 6) | 0.71 ± 0.441 |
| Capecitabine in presence of axitinib (n = 6) | 0.89 ± 0.520 |
| 5-FU alone (n = 3) | 1.11 ± 0.455 |
| 5-FU in presence of axitinib (n = 3) | 1.05 ± 0.506 |
| 5-DFUR alone (n = 4) | 0.96 ± 0.400 |
| 5-DFUR in presence of axitinib (n = 4) | 0.77 ± 0.125 |
| 5-DFC alone (n = 5) | 0.98 ± 0.499 |
| 5-DFC in presence of axitinib (n = 5) | 0.78 ± 0.147 |
| Cisplatin alone (n = 7) | 1.25 ± 0.095 |
| Cisplatin in presence of axitinib (n = 7) | 1.61 ± 0.772 |
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Clearance is defined as the volume of blood from which drug can be completely removed per unit of time. CL/F for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. CL/F for capecitabine in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (capecitabine alone) on Cycle 2 Day 1.
| Liter/hr | Axitinib + Capecitabine + Cisplatin (PK Expansion Cohort) |
|---|---|
| Axitinib alone (n = 9) | 48.55 (25.71 to 91.70) |
| Axitinib in combination with chemotherapy (n = 9) | 37.69 (19.96 to 71.19) |
| Capecitabine alone (n = 6) | 217.60 (118.45 to 399.74) |
| Capecitabine in presence of axitinib (n = 6) | 368.47 (200.58 to 676.89) |
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It is defined as the volume of blood from which drug can be completely removed per unit of time. Clearance for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate) in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin alone) on Cycle 2 Day 1.
| Liter/hr | Axitinib + Capecitabine + Cisplatin (PK Expansion Cohort) |
|---|---|
| Cisplatin alone | 30.94 (26.03 to 36.77) |
| Cisplatin in presence of axitinib | 32.50 (27.35 to 38.63) |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz/F is influenced by the fraction absorbed. Vz/F for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Vz/F for capecitabine in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (capecitabine alone) on Cycle 2 Day 1.
| Liter | Axitinib + Capecitabine + Cisplatin (PK Expansion Cohort) |
|---|---|
| Axitinib alone (n = 9) | 344.87 (202.24 to 588.09) |
| Axitinib in combination with chemotherapy (n = 9) | 171.83 (100.77 to 293.01) |
| Capecitabine alone (n = 6) | 190.94 (89.08 to 409.30) |
| Capecitabine in presence of axitinib (n = 6) | 425.00 (198.27 to 911.02) |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Clearance for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate) in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin alone) on Cycle 2 Day 1.
| Liter | Axitinib + Capecitabine + Cisplatin (PK Expansion Cohort) |
|---|---|
| Cisplatin alone | 55.35 (41.12 to 74.51) |
| Cisplatin in presence of axitinib | 70.32 (52.24 to 94.66) |
Genetic variants of uridine diphosphate (UDP)- glucuronosyl transferase 1A1 (UGT1A1) gene which were assessed for genotyping included UGT1A1\*60, UGT1A1-3156, UGT1A1 Promoter thymine adenine (TA) repeat (UGT1A1\*28, UGT1A1\*36, UGT1A1\*37), UGT1A1\*6 and UGT1A1\*27.
No measurements were reported for this outcome.
Number of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are those with disappearance of all target lesions. PR are those with at least 30 percent (%) decrease in sum of the longest dimensions of target lesions taking the baseline sum of the longest dimensions as a reference.
| percentage of participants | Axitinib + Capecitabine + Cisplatin |
|---|---|
| Percentage of Participants With Objective Response (OR) | 36.36 (17.2 to 59.34) |
Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response. CR = disappearance of all target lesions. PR = at least 30% decrease in sum of the longest dimensions of target lesions taking the baseline sum of the longest dimensions as a reference.
| months | Axitinib + Capecitabine + Cisplatin |
|---|---|
| Duration of Response (DR) | 9.07 (6.44 to 20.20) |
Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death"). PD was a\>=20% increase in sum of the longest dimensions of target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.
| months | Axitinib + Capecitabine + Cisplatin |
|---|---|
| Progression-Free Survival (PFS) | 3.75 (2.92 to 9.40) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib + Capecitabine + Cisplatin | — | 12/22 (54.5%) | 22/22 (100%) |
| Event | Axitinib + Capecitabine + Cisplatin |
|---|---|
| Disease progressionGeneral disorders | 2/22 |
| BradycardiaCardiac disorders | 1/22 |
| EnterocolitisGastrointestinal disorders | 1/22 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/22 |
| Gastrointestinal perforationGastrointestinal disorders | 1/22 |
| NauseaGastrointestinal disorders | 1/22 |
| VomitingGastrointestinal disorders | 1/22 |
| Decreased appetiteMetabolism and nutrition disorders | 1/22 |
| HeadacheNervous system disorders | 1/22 |
| HypoaesthesiaNervous system disorders | 1/22 |
| Event | Axitinib + Capecitabine + Cisplatin |
|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 20/22 |
| NauseaGastrointestinal disorders | 17/22 |
| FatigueGeneral disorders | 17/22 |
| StomatitisGastrointestinal disorders | 16/22 |
| HypertensionVascular disorders | 16/22 |
| NeutropeniaBlood and lymphatic system disorders | 14/22 |
| ThrombocytopeniaBlood and lymphatic system disorders | 12/22 |
| DiarrhoeaGastrointestinal disorders | 12/22 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 12/22 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 12/22 |
| Age Continuous(years) | Axitinib + Capecitabine + Cisplatin |
|---|---|
| Mean | 59.3 ± 11.5 |
| Sex: Female, Male(Participants) | Axitinib + Capecitabine + Cisplatin |
|---|---|
| Female | 6 |
| Male | 16 |
The record gives a start of Apr 2009, a primary completion of Dec 2009 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib